Figure 2From: XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis Kaplan-Meier curves for survival (left) and PFS (right) according to treatment allocation. Back to article page